NCT03199274View on ClinicalTrials.gov

Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

February 27, 2024

Study Completion Date

December 31, 2025

Conditions
Hepatocellular Carcinoma
Interventions
PROCEDURE

Yttrium-90 Microsphere Radioembolization

Undergo standard of care Y-90 radioembolization

DRUG

Perflutren Protein-Type A Microspheres

Given IV.

PROCEDURE

Dynamic Contrast-Enhanced Ultrasound Imaging

Undergo CEUS

Trial Locations (1)

19107

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Thomas Jefferson University

OTHER

NCT03199274 - Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer | Biotech Hunter | Biotech Hunter